Lipobalanced long chain testosterone esters for oral delivery
AssigneeLipocine Inc.
InventorsSatish Kuma Nachaegari, Chandrashekar Giliyar, Raj Patel, Nachiappan Chidambaram, Srinivasan Venkateshwaran, Mahesh V. Patel
Life of this patent
Estimating the term…
Abstract
The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier.
Claims21
A method of treating an individual, said method comprising administering, once or twice a day, to an individual in need of treatment one, two, or three unit dosage forms each unit dosage form comprising a composition having a therapeutically effective amount of a lipobalanced testosterone prodrug and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a therapeutically effective amount of (a) a lipobalanced testosterone prodrug which is not a lipobalanced T13 or T14 ester and (b) a pharmaceutically acceptable carrier.
A method of treating an individual while maintaining one or more biomarkers within an acceptable range, said method comprising:
- administering to said individual a pharmaceutical composition comprising a therapeutically effective amount of (a) a T13 ester, a T14 ester, or lipobalanced testosterone ester or lipobalanced testosterone prodrug in an amount sufficient to maintain one or more biomarkers within an acceptable range or improve the biomarker and (b) a pharmaceutically acceptable carrier.
21-25. (canceled)
Dependencies are inferred from the claim text.